Simultaneous resistance to an array of drugs with different cytotoxic activities is a property of Saccharomyces cerevisiae, in which the protein Pdr3p has recently been shown to play a role as a transcriptional regulator. We provide evidence that the yeast PDR3 gene, which encodes a zinc finger transcription factor implicated in certain drug resistance phenomena, is under positive autoregulation by Pdr3p. DNase I footprinting analyses using bacterially expressed Pdr3p showed specific recognition by this protein of at least two upstream activating sequences in the PDR3 promoter. The use of lacZ reporter constructs, a mutational analysis of the upstream activating sequences, as well as band shift experiments enabled the identification of two 5 TC CGCGGA3 sequence motifs in the PDR3 gene as consensus elements for the binding of Pdr3p. Several similar sequence motifs can be found in the promoter of PDR5, a gene encoding an ATP-dependent drug pump whose Pdr3p-induced overexpression is responsible for drug resistance phenomena. Recently one of these sequence elements was shown to be the target of Pdr3p to elevate the level of PDR5 transcription. Finally, we provide evidence in the absence of PDR1 for a PDR3-controlled transcriptional induction of the drug pump by cycloheximide and propose a model for the mechanism governing the transcriptional autoregulation of Pdr3p.
The diverse responses of eukaryotic cells to variations in the external environment are essential in shaping their identities. In this respect, one of the most important and general phenomena is the multidrug resistance process in which a cell can respond to a wide range of unrelated compounds. This process seems to apply to the vast majority of eukaryotic cells and has considerable fundamental and applied implications in both medicine and agriculture. The known key molecules in this resistance phenomenon are the membrane proteins belonging to either ABC (ATP-binding-cassette) or MFS (major facilitators superfamily) transport family. In the yeast Saccharomyces cerevisiae, genes of the ABC family include STE6, a homolog of the mammalian MDR1 gene (21, 22) whose product is involved in the secretion of the mating pheromone a, and the genes PDR5 (4), also known as STS1 (6) , and SNQ2 (34) , which are involved in the resistance to many different drugs. Many other ABC or MFS homologs are being discovered in the framework of the European project of systematic sequencing of the yeast genome (3) , demonstrating the importance and complexity of this phenomenon.
The regulatory elements controlling the expression of these transporter-encoding genes are poorly understood. Two networks of regulators are known to be involved in the drug resistance phenomenon in S. cerevisiae: (i) Yap1p, a leucine zipper factor that acts on the gene YCF1, an ABC homolog of the human cystic fibrosis transmembrane conductance regulator factor (25, 38) , and Yap2p, a homologous factor conferring cadmium resistance (9, 41) , and (ii) Pdr1p and Pdr3p, which belong to the C6 zinc cluster family of transcriptional regulatory proteins, including the well-characterized Gal4p. Pdr1p and Pdr3p control the production of Pdr5p, an ABC transporter responsible for multiple-drug resistance phenotypes (2, 3) . The present work focuses on the properties of Pdr3p, a recently discovered transcription factor (12) which is homologous to Pdr1p, the first regulatory element of this system to have been characterized (1) . The role of PDR1 is well documented by genetic experiments showing that the PDR1 locus is associated with resistance to more than 20 structurally unrelated inhibitors of both cytoplasmic and mitochondrial functions (2) or with permeability to small molecules like estradiol (16) . PDR1-mediated cycloheximide resistance requires the presence of PDR5, and several pdr1 mutants have an increased level of PDR5 mRNA (4, 23) . Like PDR1, PDR3 regulates the expression of PDR5, and mutants of PDR1 or PDR3 overexpress PDR5 mRNA (4, 23) . The molecular functions of Pdr3p are beginning to be clarified. When different parts of the PDR3 gene were fused to the DNA-binding domain of LexA (12) , it was found that two Pdr3p domains could act as transcriptional activators, a situation reminiscent of the properties of Gal4p. Recently, a Pdr3p-binding site was characterized in the PDR5 promoter (20) , and activation of PDR5 by either Pdr1p or Pdr3p induces the cycloheximide resistance process, while the oligomycin resistance phenomenon is clearly PDR5 independent (20) . An interesting point is to elucidate the respective roles of these two highly similar transcription factors. PDR1 appears to have a predominant role in the immediate response to numerous variations of the external cell conditions. Indeed, deletions of PDR1 make the cells more sensitive to cycloheximide than do PDR3 deletions (12, 20) . However, disruption of both PDR1 and PDR3 dramatically increases sensitivity to both cycloheximide and oligomycin compared with a single disruption, which testifies to the important role of PDR3 in both phenomena (12) .
In seeking to more fully understand the role of Pdr3p, we have studied its binding to the PDR3 promoter. This investigation led to the discovery of two Pdr3p-binding sites in the PDR3 promoter. We also discovered that transcription of PDR3 can be governed by an autoregulatory circuit composed of the two PDR3 upstream activating sequence (UAS PDR3 ) sites upstream from the transcription start of the gene. This PDR3 autoregulatory loop could promote the rapid PDR5 transcription in response to the external presence of cycloheximide. This positive autoregulation of PDR3, along with its activation by Pdr1p, constitutes an important difference between the expression of the two genes. This observation indicates that PDR1 and PDR3 have different patterns of expression, which is likely to be an important aspect of the drug response phenomenon.
MATERIALS AND METHODS
Strains and growth conditions. All S. cerevisiae strains used in this study were isogenic to FY1679-28C (a ura3-52 trp1⌬63 leu2⌬1 his3⌬200), FY1679-28C/ pdr3::HIS3 (a ura3-52 trp1⌬63 leu2⌬1 pdr3::HIS3), and FY1679-28C/pdr3::HIS3 pdr1::TRP1 (a ura3-52 pdr1::TRP1 leu2⌬1 pdr3::HIS3) and have been described elsewhere (12) . The yeast strains deleted for pdr1 and/or pdr3 are also called ⌬pdr1 and/or ⌬pdr3. S. cerevisiae was transformed after lithium chloride treatment as described by Ito et al. (19) .
Strains were grown at 30ЊC in minimal medium (0.67% yeast nitrogen base) supplemented with the appropriate nutritional requirements. Sugars sterilized by filtration were added after autoclaving of the media at a final concentration of 2%, and antibiotics were added at the indicated concentrations for drug sensitivity assays. For the preparation of protein extracts and galactose induction, strains were grown in glucose-containing medium to an optical density at 600 nm (OD 600 ) of 1. Cells were washed with water and resuspended in 5 ml of galactose (2%)-sucrose (1%) medium. After 5 h of growth, cells were harvested by centrifugation.
Escherichia coli XL1 blue was used for plasmid construction, whereas E. coli
] was used to produce the glutathione S-transferase (GST)-Pdr3p fusion protein.
Plasmids, oligonucleotides, and DNA manipulation. A translational fusion between the PDR3 gene and the E. coli lacZ gene was constructed by inserting a PvuII fragment (extending from bp Ϫ1548 in the PDR3 promoter to bp ϩ263 in the PDR3 open reading frame from the start of transcription) into the SmaI site of Yep367 (26) . This plasmid contains the 2m origin, LEU2, and the lacZ gene without its own AUG. The resulting recombinant was designated p3Z28.
Two-base substitution mutations were introduced into one or both of the Pdr3p-binding sites by PCR. Plasmid p3Z28 served as template for mutagenesis. Four mutagenic oligonucleotides were synthesized and used to change two bases (lowercase) in each Pdr3p-binding site: D1, GTTCaGaGGAGCTGCCTCC; G1, GGAGGCAGCTCCtCtGAAAC (upstream binding site [UAS1] underlined); D2, CGGACTTTCaGaGGAATAATA; and G2, TATTATTCCtCtGAAAGTC CG (downstream binding site [UAS2] underlined). The three mutated fragments obtained by PCR, mutations in the first UAS (M1), the second UAS (M2), or both (M1M2), were introduced in two different plasmids linearized at the SacII sites: pFL38-PP3 (ARS1 CEN4 URA3 PDR3 encoded under the control of its own promoter) and p3Z28 (described above) by in vivo homologous recombination in yeast cells (17, 28) . The resulting plasmids were designated pFL38-PP3/M1, pFL38-PP3/M1M2, p3Z28/M1, p3Z28/M2, and p3Z28/M1M2. These constructions were all sequenced around the Pdr3p-binding sites. The centromeric plasmid pFL38 has been previously described (8) .
The plasmid construction encoding PDR3 under the control of the GAL1 promoter, called pYE-PDR3, was obtained by introducing the KpnI-BamHI fragment of pKSPDR3 (12) into the same sites in pYE-DP1/8-2 (2m URA3) described by Pompon and Nicolas (28) .
Plasmids encoding PDR3 under the control of its own promoter, pFL38-PP3 (ARS1 CEN4 URA3) and pFL44-PP3 (2m URA3), are described in reference (12) .
To express the GST-Pdr3p fusion protein in E. coli, a PCR fragment of PDR3 amplified with two oligonucleotides situated in the N-and C-terminal regions of PDR3 and containing two BamHI sites (CGTGGATCCATGAAAGTGAAGA AATCA and CGGGGATCCTCATAAGAAGGGATATGA) was inserted into the BamHI site of pGEX-2T (35) to produce pGEX-2TPDR3.
Plasmids EM109, pRS316-PDR1, and Yep24-PDR1 were generous gifts of E. Balzi and A. Goffeau. EM109 is a pBluescript SK plasmid containing at the SmaI site a fragment from 1,246 bp upstream of the initiation codon of PDR5 to 89 bp downstream. pRS316-PDR1 and Yep24-PDR1 are yeast shuttle plasmids (ARS1 CEN4 URA3 and 2m URA3, respectively) containing 816 bp of the PDR1 promoter and the PDR1 open reading frame inserted at the SmaI and BamHI sites.
Northern (RNA) analysis. Yeast cells (⌬pdr1 ⌬pdr3) transformed with pFL38-PP3 or pFL38-PP3/M1M2 used for Northern analyses were grown in minimal medium to an OD 600 of 1.0, and then cycloheximide at a final concentration of 0.3 g/ml was added. Total RNA was isolated from cells as described previously (32) at different times after cycloheximide addition. Thirty micrograms of RNA was separated on agarose gel containing 6% formaldehyde, blotted to a nylon membrane (Hybond Nϩ; Amersham), and hybridized to DNA probes as indicated by the supplier. The membrane was probed both with a 1-kb EcoRIHindIII DNA fragment of the ACT1 gene from plasmid pYA208 (15) and with the PDR5 promoter fragment (SmaI-HindIII) purified from plasmid EM109. Signals were quantified with a PhosphorImager (Molecular Dynamics), and measurements were made with ImageQuant software version 3.3. Radiolabeling of the probes was done by the random-priming procedure (Kit Nonaprime; Appligene).
Preparation of crude protein extracts and purification of the E. coli fusion protein GST-Pdr3p. S. cerevisiae protein extracts used for gel retardation assays and ␤-galactosidase measurements were prepared as described by Thomas et al. (39) . Protein concentrations were estimated by the method of Bradford (10) .
Protein extracts of E. coli cells transformed with the expression plasmid pGEX-2TPDR3 were prepared from 200-ml cultures grown to an OD 600 of 0.8 and then subjected to induction with 0.1 mM isopropylthiogalactopyranoside (IPTG) for 3 h. Cultures were cooled on ice, and cells were washed once in ice-cold G buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.1 mM ZnSO 4 , 0.5% Nonidet P-40). Cells were resuspended in 20 ml of G buffer and broken by sonication. Cell debris was removed by centrifugation for 15 min at 10,000 ϫ g. Four hundred microliters of glutathione-agarose beads (Pharmacia) was added to the supernatant and mixed gently in a cold room for 30 min. The beads were then washed four times with 50 ml of G buffer, and the GST-Pdr3p fusion proteins were eluted twice by adding 500 l of fresh 50 mM Tris-HCl (pH 8.0)-15 mM reduced glutathione. The supernatant with a protein concentration of about 150 g/ml was frozen at Ϫ20ЊC after addition of glycerol to a final concentration of 20%.
␤-Galactosidase activity determinations. ␤-Galactosidase activity was determined in crude extracts by using o-nitrophenyl-␤-D-galactopyranoside (ONPG) as the substrate as described by Miller (24) . Each value reported is the average of determinations from at least four independent transformants.
Gel retardation assays. Fragments for gel retardation assays and DNase I footprinting were end labeled by using ␣- Proteins were diluted into binding buffer immediately before use. Samples were incubated for 20 min at 28ЊC, put on ice, and analyzed by pore exclusion limit electrophoresis (30) . Binding reaction mixtures were loaded on 3 to 8% polyacrylamide gels (polyacrylamide/bis ratio of 29:1) containing 0.25ϫ Tris-borate-EDTA with a 3 to 8% glycerol gradient at 350 V for 8 h at 4ЊC. Gels were dried and exposed for autoradiography.
RESULTS

Two binding sites are recognized by Pdr3p in the PDR3
promoter. The recent characterization of one sequence element of the PDR5 promoter bound by the N-terminal part of the Pdr3p protein (20) supports the notion that Pdr3p is a direct activator of PDR5. To evaluate the binding properties of our E. coli-expressed GST-Pdr3p fusion protein, which contains the entire Pdr3p fused to GST, we carried out a systematic analysis of its interaction with the PDR5 promoter. To this end, we used a rapid and accurate method which takes advantage of a two-dimensional band shift assay performed at two different temperatures (7). As expected from previous studies (20) , a restriction fragment containing the strong Pdr3p-binding site at position Ϫ135 (upstream from the transcription start [4] ) with the sequence 5ЈTCCGCGGA3Ј was clearly shifted from the diagonal. In addition, two other restriction fragments were also shifted from the diagonal, suggesting that Pdr3p has at least three binding sites in the PDR5 promoter (11b).
Analysis of the PDR3 promoter sequence reveals two motifs analogous to those found in the PDR5 promoter. A two-dimensional gel electrophoresis approach was used to study the interactions between Pdr3p and its own promoter and revealed the existence of two binding sites for Pdr3p (data not shown). To obtain better evidence of these binding sites of Pdr3p on its own promoter, we carried out DNase I protection assays with a PCR-generated fragment of the PDR3 promoter extending from bp Ϫ248 to ϩ33. This fragment overlaps two sequence elements at Ϫ106 (UAS1) and Ϫ139 (UAS2) which are in the middle of the two regions protected by the GST-Pdr3p fusion protein ( Fig. 1) . In both cases, the protected region is a staggered 18-bp region on both strands, and the conserved sequence 5ЈTCCGCGGA3Ј is perfectly centered in this protected region (Fig. 1A) . A DNase I-hypersensitive site at FIG. 1. DNase I footprinting analysis of the proximal region of the PDR3 promoter demonstrates the presence of two Pdr3p-binding sites. The PDR3 promoter fragment (Ϫ248 to ϩ33) was generated by PCR and end labeled on the coding (A) or noncoding (B) strand. It was then subjected to DNase I digestion (0.05 and 0.2 g) with (ϩ) or without (Ϫ) prior incubation with 1.5 g of the purified E. coli GST-Pdr3p fusion protein and analyzed by electrophoresis through denaturing polyacrylamide gels. Footprints are indicated on the right of each footprinting ladder between two arrows. UAS1 and UAS2 indicate the minimal sequence elements shown by band shift experiments to be sufficient to bind either E. coli GST-Pdr3p or Pdr3p from yeast extracts (data not shown). HP, the DNase I-hypersensitive site. (C) The same type of experiment conducted with mutated PDR3 promoter sequences. M1 and M2 are the mutated forms of UAS1 and UAS2, respectively. In each case, the mutation corresponds to a change of the UAS sequence from 5ЈTCCGCGGA3Ј to 5ЈTCAGAGGA3Ј. position Ϫ87 was clearly induced by the binding of the protein and could correspond to a biologically significant conformational change in DNA structure. The fact that the GST-Pdr3p fusion protein recognizes and protects the sequence 5ЈTCC GCGGA3Ј, which was previously described as a binding site for Pdr3p in the PDR5 promoter (20) , indicates that the GST part of the fusion protein does not alter the DNA-binding properties of Pdr3p.
To further examine the interactions of Pdr3p with the two UASs, we constructed mutants in which either UAS1 (mutant M1) or UAS2 (mutant M2) were altered by the same base changes (TCCGCGGA to TCAGAGGA). DNase I footprinting experiments were then conducted with fragments of the PDR3 promoter carrying M1, M2, or both M1 and M2 mutations. Clearly (Fig. 1C) , the mutated UAS cannot bind Pdr3p, but the remaining wild-type UAS is apparently unaffected in its binding properties. In other words, binding of GST-Pdr3p to the two UASs seems additive. We also examined in a titration experiment (Fig. 1D ) the effects of increasing amounts of Pdr3p on the DNase I footprints of the complex. Very low amounts of protein (probably less than 5 nM) can distinguish between the two UASs. UAS2 is completely protected by GSTPdr3p when UAS1 is only partially protected. This observation led us to conduct a quantitative analysis of the binding of GST-Pdr3p to the two UASs. Electrophoretic mobility shift assays with a radiolabeled DNA fragment containing the two UAS elements and increasing concentrations of the purified Pdr3p protein demonstrated that two types of complexes, corresponding to single (I) and double (II) occupancy of the two UASs, can be resolved ( Fig. 2A) . We could also observe that mutations in either UAS (M1 or M2) resulted in the formation of only one complex, thus confirming that the number of resolvable complexes corresponds to the number of binding sites (data not shown). To determine whether GST-Pdr3p binds cooperatively to the two UASs, we used various concentrations of GST-Pdr3p in the binding reactions. At low concentrations of Pdr3p, only complex I was apparent ( Fig. 2A) . Increasing concentrations of Pdr3p enhanced progressively the formation of complex II. The precise levels of complexes I and II and free DNA were quantified. The overall results and the sigmoidal curve for the formation of complex II are reminiscent of a cooperative binding process (5) . However, careful quantification of the results by using equations previously described (40) indicates that the degree of cooperativity is weak. More precisely, the relative dissociation constant of complex II is no more than 1.5-to 2-fold less than that of complex I.
To investigate whether the two UAS PDR3 sequences in the PDR3 promoter could form DNA-protein complexes with Pdr3p synthesized in the yeast cytoplasm, gel retardation assays were performed with a labeled fragment containing PDR3 promoter sequences (from positions ϩ33 to Ϫ248) and yeast extracts from a Pdr3p-overproducing strain. Figure 3 shows that increasing amounts of yeast extract added to a DNA fragment corresponding to the wild-type sequence led to the formation of two predominant complexes, C1 and C2. Two other high-molecular-weight complexes could be seen at high protein concentrations. None of these complexes could be detected with yeast extracts from a strain deleted for both PDR1 and PDR3 or from the wild-type strain, which does not overproduce Pdr3p (data not shown). These results demonstrate that the formation of complexes C1 and C2 is Pdr3p dependent, but they do not prove that Pdr3p is directly responsible for the formation of the complexes. This point was further confirmed by analyses of the mutants in the two UAS PDR3 sequences. Mutation M1 or M2 clearly affected the formation of complexes C1 and C2, and when the double mutant was used as a substrate for the yeast extract of the overproducing strain, no complex could be seen (Fig. 3) . When either UAS1 or UAS2 was mutated, complexes C1 and C2 were formed, but in proportions which differed from those of the wild-type sequence (Fig. 3) . Also, the formation of high-molecular-weight complexes was severely affected by the presence of mutation M1 or M2. To summarize, the sizes of complexes C1 and C2, their dependence on the presence of Pdr3p, and their total absence when both UAS1 and UAS2 are mutated strongly argue in favor of a direct involvement of Pdr3p in the formation of these complexes. The reasons why complex C2 can be formed even when one of the UASs is mutated may be that Pdr3p from yeast extracts is different from its E. coli version, The Pdr3p protein controls transcription of its own gene. The data presented above show that Pdr3p is able to specifically interact with the PDR3 promoter. The in vivo activating properties of the Pdr3p-DNA complexes can be assessed by fusing the PDR3 promoter to the lacZ reporter gene. The PDR3-lacZ fusion gene contained 1,548 bp of the sequence upstream from the transcription start of PDR3. The corresponding multicopy plasmid was then used to transform different isogenic strains deleted for PDR3 and expressing different levels of Pdr3p. Thus, variations in gene copy number obtained by using either 2m or centromeric plasmids or by using the strong GAL1 promoter rather than the PDR3 promoter allowed us to produce various quantities of Pdr3p in vivo and to estimate their effects on expression of the PDR3-lacZ fusion gene. A control experiment was carried out to ascertain that the transcription start in the PDR3-lacZ fusion was identical to that of the wild-type PDR3 gene (data not shown). The results are presented in Table 1 . Clearly, the production of ␤-galactosidase reflects the production level of Pdr3p. Between a low level obtained with a CEN4 plasmid and the PDR3 promoter and a high level obtained with a 2m plasmid and the strong GAL1 promoter, there was a 20-fold increase in ␤-galactosidase activity. An intermediate situation led to an intermediate level of ␤-galactosidase activity.
To obtain further evidence that Pdr3p is indeed involved in the control of transcription of its own gene, we took advantage of the mutations in the two UASs previously described. The properties of the three mutated constructs and the wild-type sequence were analyzed in vivo when Pdr3p was produced from the GAL1 promoter. We observed that expression of the PDR3-lacZ fusion gene was totally abolished when the two FIG. 3 . Effects of mutations in UAS1 or UAS2 on the formation in vitro of DNA-protein complexes with yeast extracts overproducing Pdr3p. A 281-bp DNA fragment overlapping the two UASs was labeled and incubated with extracts of a yeast strain (⌬pdr1 ⌬pdr3) overproducing Pdr3p (GAL1 promoter). Increasing amounts (1.5 to 30 g) of total proteins were added to the wild-type or mutated (M1, M2, or M1M2; see Fig. 4 ) PDR3 promoter fragment. Samples were then fractionated on a 3 to 8% gradient polyacrylamide gel by pore exclusion limit electrophoresis. The arrows indicate the positions of the two major UAS-dependent DNA-protein complexes (C1 and C2). Competition experiments were conducted with cold oligonucleotides. The complexes C1 and C2 were no longer visible in the presence of 100-fold molar excesses of the oligonucleotides corresponding to UAS1, whereas a nonspecific oligonucleotide had no effects in the same conditions (data not shown).
FIG. 4. Effects of mutations in UAS1
and/or UAS2 on the in vivo properties of the PDR3 promoter. The properties of the PDR3 promoter were assessed in a genetic context in which the chromosomal copy of PDR3 was deleted, using a PDR3-lacZ reporter gene (p3Z28). Pdr3p was produced from a PDR3 gene under the control of the GAL1 promoter on a multicopy vector (pYE-DP1/8-2). Two base changes were introduced in UAS1 (p3Z28/M1) or UAS2 (p3Z28/M2); a construct with mutations in both UAS sequences was also constructed (p3Z28/M1M2). ␤-Galactosidase activity is reported as the mean Ϯ standard deviation from at least four independent experiments. The ␤-galactosidase activity of the wild-type strain FY1679-28C transformed with p3Z28 is 25 Ϯ 2 nmol/min/mg of protein. a A PDR3-lacZ reporter gene on plasmid p3Z28 (see Materials and Methods) was used in three different isogenic contexts to assess the effects of the in vivo amounts of Pdr3p or Pdr1p. These two proteins were produced either from their own promoters or from the strong GAL1 promoter (vector pYE-DP1/8-2) in multicopy or from ARS CEN plasmids. The latter plasmids carrying either PDR3 or PDR1 are presented in the first column. To estimate ␤-galactosidase production, cells were grown on minimal glucose medium except that cells harboring pYE-DP1/8-2 and pYE-PDR3 were first grown on glucose before induction on minimal galactose medium for 5 h. Each value reported for ␤-galactosidase activity is the average of determinations with the standard deviation from at least four independent transformants. The level of production of PDR3-driven ␤-galactosidase for the wild-type strain (FY1679-28C) was 50 Ϯ 5 U. The different genetic backgrounds were provided by strains FY1679-28C/pdr3::HIS3, FY1679-28C/pdr1::TRP1/pdr3::HIS3, and the corresponding double disruptants; these strains were previously described (12 (Fig. 4, 3Z28/M1M2 ). Mutation of the upstream UAS1 (Fig. 4 , 3Z28/M1) reduced the ␤-galactosidase activity to 30% of its wild-type level, whereas mutation of the downstream UAS2 (Fig. 4 , 3Z28/M2) reduced this reporter activity to about 70%. These results give strong support to the ideas that (i) Pdr3p interacts with its own promoter by recognizing the two UAS-related sequences, (ii) both UASs are required for full transcriptional activation, and (iii) the two UAS-related sequences do not contribute equally to the activator effect. The upstream sequence, UAS1, has a predominant effect on downstream transcription. This finding is all the more surprising because the two UAS sequences are apparently identical. There could be two possible explanations: either the sequence context of each UAS is important for the binding of the activator, although we previously observed that Pdr3p has a higher affinity for UAS2 (Fig. 1C) , or the distance of UAS1 from the transcription start is more suitable for an activator effect. Role of Pdr1p, the homolog of Pdr3p, in the positive autoregulation of PDR3. The high degree of identity between the coding sequences of PDR1 and PDR3 (12) suggests that the encoded proteins can share target genes. In this respect, it was of interest to determine whether Pdr1p is also able to control the expression of PDR3. To this end, strains deleted for both PDR1 and PDR3 and plasmids producing Pdr1p at different concentrations were used to analyze the autoregulation process of PDR3 (Table 1) . It can be observed that disruption of PDR1 always reduces the PDR3-driven ␤-galactosidase production. Correlatively, production of Pdr1p from a PDR1 gene carried on a plasmid restores ␤-galactosidase synthesis according to the plasmid copy number. Interestingly, this restoration effect can also be obtained by the production of Pdr3p, which indicates the high degree of similarity between the functions of the two proteins. All of these data support the previous suggestion (20) that Pdr3p and Pdr1p may have similar DNAbinding sites. Certainly, further experiments are required to define the interactions of Pdr1p with its targets in both PDR3 and PDR5 promoters and to explain the relative roles of Pdr1p and Pdr3p in control of the transcription of these genes.
PDR3 autoactivation is involved in the drug resistance phenomenon. If Pdr3p is able to activate its own promoter by interacting with the two UASs, one might wonder whether this property is relevant to the drug resistance phenomenon. To study this point, it was necessary to remove PDR1, since Pdr1p could conceal a more discrete effect of Pdr3p. We then used a strain in which both PDR1 and PDR3 were deleted and which was transformed with a centromeric plasmid containing the PDR3 gene and its promoter region. Mutated promoter sequences were also constructed to assess the role of the autoactivation effect. In agreement with the data presented above, we thus modified the two UAS elements to block the autoactivation process. Both wild-type and mutated forms of the PDR3 gene were then tested for the ability to confer a drug resistance phenotype to the transformed strain (Fig. 5) . The yeast strain in which PDR1 and PDR3 were deleted was highly sensitive to the external presence of drugs. For instance, in the case of cycloheximide, a concentration of 0.05 g/ml was sufficient to affect growth on minimal medium. This value, defined as the minimal inhibitory drug concentration, was increased to 0.4 g/ml when the same strain was transformed with the centromeric plasmid pFL38-PP3, which contains a wild-type copy of the PDR3 gene. Mutations in the promoter region of this gene which affect either UAS1 (M1) or the two UASs (M1M2) completely abolished the drug resistance response. This finding clearly indicates that the two UAS sequences, as cis-acting signals, are necessary to confer the resistance phenotype. Moreover, in the absence of PDR1, the trans-acting product mediating this effect is clearly Pdr3p dependent. Thus, the transcriptional autoactivation process of PDR3 in the absence of the PDR1 gene is involved in the process that confers a cycloheximide-resistant phenotype.
Kinetics of accumulation of PDR5 mRNA in response to cycloheximide. The toxicity of cycloheximide dictates that PDR5 must be functionally or biosynthetically activated quickly in response to cycloheximide exposure. We examined the kinetics of PDR5 mRNA accumulation in genetic contexts in which the autoregulatory loop of PDR3 was either active or inactive as a result of mutations in the upstream UAS sequences. Transformed yeast strains, identical to those previously used to show that the PDR3 autoactivation process was involved in the drug resistance phenomenon, were grown in minimal medium, induced in log phase with 0.3 g of cycloheximide per ml, and harvested at different times shortly after cycloheximide induction. Total RNA was prepared, and the steady-state levels of PDR5 mRNA were measured during the course of cycloheximide treatment after RNA electrophoresis and blotting. The actin mRNA levels were also evaluated as a control for the amount and integrity of RNA loaded onto each lane of the RNA gel. Signals were quantified by PhosphorImager (Molecular Dynamics) analysis. We observed (Fig. 6 ) that the threefold increase in the steady-state level of PDR5 mRNA after 2 h in the presence of cycloheximide was dependent on the presence of wild-type UAS PDR3 upstream from PDR3. In other words, the cycloheximide induction of PDR5 mRNA is, at least in part, dependent on the active positive autoregulatory loop of PDR3.
DISCUSSION
Since the initial discovery of the PDR3 locus (36, 37) , proof has accumulated that Pdr3p is a zinc finger-containing transcription factor which plays an important role in the pleiotropic resistance phenotype (12, 13, 20) . The recent demonstration that Pdr3p controls the expression of PDR5, a membrane transporter-encoding gene, by interacting with its promoter region was the first characterization of one of the multiple targets of this gene product (20) . Here we provide molecular evidence of new Pdr3p targets in the PDR3 promoter itself. This latter interaction is the molecular basis of a positive autoactivation process which is able to control a cycloheximide resistance phenotype. FIG. 5 . PDR3 autoactivation is involved in the drug resistance phenotype. The ⌬pdr1 ⌬pdr3 yeast strain was transformed with a centromeric plasmid carrying PDR3 (pFL38-PP3), and growth in the presence of increasing amounts of cycloheximide was estimated after 3 days at 30ЊC on minimal glucose medium. The same experiment was conducted when the PDR3 promoter was mutated as previously indicated (Fig. 4) in UAS1 alone (pFL38-PP3/M1) or in UAS1 and UAS2 (pFL38-PP3/M1M2). The wild-type strain FY1679-28C can grow in the presence of 0.4 g of cycloheximide per ml.
Identification of two UAS PDR3 sites in the PDR3 promoter.
Preliminary observations by a two-dimensional electrophoresis procedure that the PDR3 promoter contains two binding sites for Pdr3p were fully confirmed by footprinting analyses. The two protected regions are centered at positions Ϫ106 (UAS1) and Ϫ139 (UAS2) from the transcription start. These two elements contain the sequence 5ЈTCCGCGGA3Ј, which had previously been found in the site for binding of Pdr3p to the transmembrane protein-encoding gene PDR5 (20) . The DNase I footprinting experiments with the wild-type and mutated sequences strengthen the view that the Pdr3p-binding site contains the palindromic sequence 5ЈCCGCGG3Ј, which, as already noted by Katzmann et al. (20) , is unusual among members of the Gal4p family because of the lack of spacing between the symmetrical CCG nucleotides (29) . Interestingly, in addition to its presence in the PDR5 promoter, the motif 5ЈTCCG CGGA3Ј recognized by Pdr3p can be found in the upstream regions of several other genes coding for transmembrane proteins, such as SNQ2 (34) and D4405 (11) , or homologous to hexose transporter-encoding genes (11a) . Further experiments are required to precisely localize and determine the functions of the Pdr3p-binding sites in these promoters, but it is already tempting to speculate that Pdr3p may be for controlling the biosynthesis of a specific class of membrane proteins.
Pdr3p and Pdr1p activate the transcription of PDR3. The presence of two UAS PDR3 sites in the PDR3 promoter is strongly suggestive of an autoregulation process. This possibility was functionally assessed by using a PDR3-lacZ fusion gene. Production of ␤-galactosidase clearly reflects the level of Pdr3p in the cell (Table 1) as well as the integrity of the PDR3 promoter sequence (Fig. 4) . Mutation of one of the UASs greatly decreases the inducibility of the adjacent gene. In this process, the most upstream UAS seems to play an important role, since its alteration greatly alters the production of ␤-galactosidase (Fig. 4) . This predominant role of UAS1 should, however, be moderated by the observation that UAS2 is the first motif to be recognized by Pdr3p in our titration experiment (Fig. 1C) . Most generally, UAS1 and UAS2 do not seem to cooperate to bind an E. coli-expressed purified form of GST-Pdr3p (Fig. 2) . However, when a yeast extract of a strain overproducing Pdr3p was added to a wild-type or mutated form of the PDR3 promoter and analyzed by gel retardation (Fig. 3) , the mutated form of the UAS seems to be able to bind Pdr3p provided that the second UAS had a wild-type sequence. This observation, which seems at variance with the data presented in Fig. 1C , suggests that a protein(s) absent from the purified form of GST-Pdr3p can enhance the binding of Pdr3p to a mutated UAS when the other UAS is active. Such auxiliary DNA-binding factors have recently been characterized in yeast cells (27) . Alternatively, one can propose that the yeast form of Pdr3p is modified by specific factors.
The high degree of identity between the coding sequences of PDR1 and PDR3, coupled with the similar phenotypic effects of these genes, strongly suggests that the functions and target genes of these loci overlap extensively. As expected, the production of Pdr1p was also related to increased PDR3-driven ␤-galactosidase activity. Correlatively, when the PDR3 gene was overexpressed (multicopy vector and strong promoter), the PDR3-driven ␤-galactosidase activity was decreased in the absence of Pdr1p. As already suggested (20) , it seems likely that Pdr1p also binds to the motif recognized by Pdr3p; further experiments are required to precisely define these interactions.
Autoregulation of PDR3 and the response to cycloheximide. Previous studies have shown that both PDR1 and PDR3 affect cycloheximide resistance of the cell by activating PDR5 expression (4, 12, 20) . We observed in this work that in a ⌬pdr1 strain, the level of resistance to cycloheximide was directly dependent on the integrity of the two UAS PDR3 sites upstream from PDR3. With a wild-type form of PDR3 carried on a centromeric plasmid, the transformed yeast strain could grow at a cycloheximide concentration of 0.3 g/ml, which is close to the limit (0.4 g/ml) when both PDR1 and PDR3 were present (Fig. 5) . The fact that the isogenic strain in which the two UASs in the PDR3 promoter were mutated could grow only on very low concentrations of cycloheximide (less than 0.05 g/ ml) clearly indicates that the transcriptional autoregulation process of PDR3 is involved in the response to cycloheximide. To further confirm this point, we analyzed the kinetics of accumulation of PDR5 mRNA in response to cycloheximide. We observed that PDR5 mRNA concentrations were threefold greater with wild-type UASs than with their mutated forms (Fig. 6 ). This observation gives credence to the role of the PDR3 autoregulatory loop in the control of PDR5 mRNA production. Although preliminary, this result strongly suggests that the PDR3 autoregulatory loop is a part of a multistep process to make cells drug resistant. The contribution of the PDR3 loop to this process remains to be assessed. This observation is reminiscent of the recent observation (43) that in the yeast Candida glabrata, the copper detoxification process is mediated by a rapid transcriptional autoregulation of the yeast transcription factor Amt1p.
Autoregulation of PDR3 and the interplay of Pdr3p and Pdr1p. It is tempting to speculate on the relative roles of Pdr3p and Pdr1p, keeping in mind that other regulatory factors such as Pdr7p and Pdr9p are certainly involved (14) . Several lines of evidence indicate that Pdr1p and Pdr3p have very similar properties: (i) their zinc finger DNA-binding regions are very similar (12), (ii) they recognize similar if not identical DNAbinding sites (reference 20 and this work), and (iii) they can cross-complement pdr1 or pdr3 mutants (3). Differences between the functions of the two proteins are nevertheless suggested by the observed phenotypes of the strains deleted for either PDR1 or PDR3. While PDR3 deletion has a very weak effect on cycloheximide sensitivity, deletion of PDR1 increases the sensitivity of the strain to the drug, and the double deletion generates a hypersensitive strain (12, 20) . This finding indicates (i) that Pdr1p plays a predominant role in the activation of PDR5 and (ii) that Pdr3p is important for achieving a fully resistant phenotype. Our study, which provides new data on FIG. 6 . Kinetics of accumulation of PDR5 mRNA in response to cycloheximide exposure. Yeast cells (⌬pdr1 ⌬pdr3) transformed either with the ARS CEN4 plasmid pFL38-PP3 carrying the wild-type PDR3 gene (A) or pFL38-PP3/M1M2 carrying a PDR3 gene mutated in its two UAS elements (B) were grown to an OD 600 of 1 and treated with cycloheximide (cyclo) to a final concentration of 0.3 g/ml for the time indicated above each lane. Total RNA was prepared, and 30 g was used in an RNA blotting assay (A). As an internal control for the loading of RNA, S. cerevisiae actin mRNA levels were analyzed. The radioactivity associated with each mRNA species was quantified with a PhosphorImager (Molecular Dynamics), and measurements were made with ImageQuant software version 3.3. The amounts of PDR5 mRNA were normalized to the corresponding actin mRNA level and plotted against exposure time to cycloheximide (B). Although Pdr1p and Pdr3p have similar functions, the expression patterns of their genes are probably different. PDR1 apparently has no trace of the sequence motif 5ЈTCCGCGGA3Ј, which could play a role in a possible autoregulation, whereas PDR3 is clearly autoregulated. In addition, Pdr1p can activate PDR3, whereas the reverse is unlikely. This circuitry reveals the predominant role of Pdr1p, which is the first to respond to many different drugs (16) , whereas Pdr3p is made, probably in large amounts, to complete the drug response. One might wonder why there are so few examples in the yeast S. cerevisiae of autoregulatory expression of a transcription factor, a process so widely observed in mammalian genes (31) . As a unicellular eukaryotic microorganism, a yeast cell is highly accessible to environmental changes in drug concentrations. The yeast response has to be both rapid and adapted to the drug concentration. The development of a rapid response could be conferred by the action of Pdr1p, which secondarily could boost the drug resistance response by activating PDR3 and its autoregulatory loop. This system seems to be more sophisticated than the recently described autoregulatory processes found in the case of copper detoxification in the yeast C. glabrata (43) or in the case of LAC9 from Kluyveromyces lactis (42) or INO4 from S. cerevisiae (33) . The most elaborate cases of both positive and negative autoregulation of transcription factors are certainly those found in the homeotic genes (18) . It is interesting that in all of these systems in which an autoregulatory loop has been demonstrated, the end result is a fine temporal tuning of complex molecular mechanisms. PDR1 and PDR3 also seem to act successively through the autoregulation loop of PDR3. These considerations suggest that in vivo, Pdr1p and Pdr3p do not represent a strictly redundant gene family of transcription activators; instead, they are regulated differently and have similar but complementary functions.
